Pfizer announces availability of Inflectra, its Remicade biosimilar

NEW YORK — Pfizer on Tuesday announced that it will begin shipping its Inflectra (infliximab-dyyb), a biosimilar of Remicade (infliximab), to U.S. wholesalers starting at the end of November. 

 

Inflectra will be the second biosimilar available in the United States, and the first biosimilar monoclonal antibody. Pfizer will introduce Inflectra at a 15% discount to the current wholesaler acquisition cost of Remicade.

 

“Biologics have revolutionized the treatment of many life-threatening and chronic diseases,” Pfizer Essential Health regional president North America Diem Nguyen said. “By introducing INFLECTRA to the U.S. marketplace, Pfizer is helping customers access an additional high-quality treatment option that promises greater savings for the healthcare system.”

 

The drug is indicated to treat adult and pediatric patients six years of age and older with moderate to severely active Crohn’s disease after an inadequate response to conventional therapy; adult patients with moderate to severely active ulcerative colitis who have an inadequate response to conventional therapy; and moderate to severely active rheumatoid arthritis in combination with methotrexate; active ankylosing spondylitis; active psoriatic arthritis; and chronic to severe plaque psoriasis.

 

“We are proud of our global leadership in biosimilars, and will continue our efforts to advance a sustainable, competitive marketplace for these therapies to deliver a high quality, consistent supply of product and long-term savings and value for patients and physicians,” Nguyen said.